Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>]
- Autores
- Martini, Nancy; Parente, Juliana Elena; Toledo, Maria Eugenia; Escudero, Graciela Estela; Laino, Carlos H.; Martínez Medina, Juan José; Echeverría, Gustavo Alberto; Piro, Oscar Enrique; Lezama, Luis; Williams, Patricia Ana María; Ferrer, Evelina Gloria
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- In the current study the ability of copper complex to exert multiple biological activities is combined with the pharmacological action of sertraline (SerH2Cl, antidepressant drug). The hydrated and anhydrous forms of the tetrachlorocuprate(II) salts, namely (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4], were synthesized and characterized by physicochemical methods. The crystal structures were determined by X-ray diffraction methods. The hydrate complex crystallizes in the monoclinic P21 space group with a =8.0807(2) Å, b =36.2781(8) Å, c =12.6576(3) Å, β =95.665(2)°, and Z =4 molecules per unit cell and the un-hydrate in P21 with a =13.8727(6) Å, b =7.5090(3) Å, c= 18.618(1) Å, β =104.563(6)°, and Z =2. It has been suggested that Cu(II) ions might be critical in the development of mood disorders, showed potent biocidal activity, and also acted as analgesic adjuvant. To improve sertraline efficiency, the antidepressant and analgesic activities of the complex have been assessed in rats denoting a marked synergistic effect. Antithyroid and antimicrobial activities were also evaluated. Because depressive disorders and hyperthyroidism diseases led to an oxidative stress state, antioxidant capability has also been tested. The complex behaved as a good superoxide radical scavenger (IC50=6.3 × 10−6 M). The ability of the complex to act as bromoperoxidase mimic was assessed. A pseudofirst order constant of k = 0.157 ± 0.007 min−1 has been determined. The complex evidences promising biological-pharmacological activities and the albumin binding studies showed a Kb of 2.90 ×103 M−1 showing an improvement in the uptake of sertraline by albumin at 8 h incubation (time required for effective interaction of sertraline with the protein).
Centro de Química Inorgánica
Instituto de Física La Plata - Materia
-
Bioquímica
Drug design
X-ray crystal structure
Pharmacological activities
Bioavailability - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/104864
Ver los metadatos del registro completo
id |
SEDICI_169105a46b759ba2ce029b409e14cf6d |
---|---|
oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/104864 |
network_acronym_str |
SEDICI |
repository_id_str |
1329 |
network_name_str |
SEDICI (UNLP) |
spelling |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>]Martini, NancyParente, Juliana ElenaToledo, Maria EugeniaEscudero, Graciela EstelaLaino, Carlos H.Martínez Medina, Juan JoséEcheverría, Gustavo AlbertoPiro, Oscar EnriqueLezama, LuisWilliams, Patricia Ana MaríaFerrer, Evelina GloriaBioquímicaDrug designX-ray crystal structurePharmacological activitiesBioavailabilityIn the current study the ability of copper complex to exert multiple biological activities is combined with the pharmacological action of sertraline (SerH2Cl, antidepressant drug). The hydrated and anhydrous forms of the tetrachlorocuprate(II) salts, namely (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4], were synthesized and characterized by physicochemical methods. The crystal structures were determined by X-ray diffraction methods. The hydrate complex crystallizes in the monoclinic P21 space group with a =8.0807(2) Å, b =36.2781(8) Å, c =12.6576(3) Å, β =95.665(2)°, and Z =4 molecules per unit cell and the un-hydrate in P21 with a =13.8727(6) Å, b =7.5090(3) Å, c= 18.618(1) Å, β =104.563(6)°, and Z =2. It has been suggested that Cu(II) ions might be critical in the development of mood disorders, showed potent biocidal activity, and also acted as analgesic adjuvant. To improve sertraline efficiency, the antidepressant and analgesic activities of the complex have been assessed in rats denoting a marked synergistic effect. Antithyroid and antimicrobial activities were also evaluated. Because depressive disorders and hyperthyroidism diseases led to an oxidative stress state, antioxidant capability has also been tested. The complex behaved as a good superoxide radical scavenger (IC50=6.3 × 10−6 M). The ability of the complex to act as bromoperoxidase mimic was assessed. A pseudofirst order constant of k = 0.157 ± 0.007 min−1 has been determined. The complex evidences promising biological-pharmacological activities and the albumin binding studies showed a Kb of 2.90 ×103 M−1 showing an improvement in the uptake of sertraline by albumin at 8 h incubation (time required for effective interaction of sertraline with the protein).Centro de Química InorgánicaInstituto de Física La Plata2017-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf76-89http://sedici.unlp.edu.ar/handle/10915/104864enginfo:eu-repo/semantics/altIdentifier/issn/0162-0134info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinorgbio.2017.05.012info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:22:57Zoai:sedici.unlp.edu.ar:10915/104864Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:22:58.135SEDICI (UNLP) - Universidad Nacional de La Platafalse |
dc.title.none.fl_str_mv |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
title |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
spellingShingle |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] Martini, Nancy Bioquímica Drug design X-ray crystal structure Pharmacological activities Bioavailability |
title_short |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
title_full |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
title_fullStr |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
title_full_unstemmed |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
title_sort |
Evidence of promising biological-pharmacological activities of the sertraline-based copper complex: (SerH<SUB>2</SUB>)<SUB>2</SUB>[CuCl<SUB>4</SUB>] |
dc.creator.none.fl_str_mv |
Martini, Nancy Parente, Juliana Elena Toledo, Maria Eugenia Escudero, Graciela Estela Laino, Carlos H. Martínez Medina, Juan José Echeverría, Gustavo Alberto Piro, Oscar Enrique Lezama, Luis Williams, Patricia Ana María Ferrer, Evelina Gloria |
author |
Martini, Nancy |
author_facet |
Martini, Nancy Parente, Juliana Elena Toledo, Maria Eugenia Escudero, Graciela Estela Laino, Carlos H. Martínez Medina, Juan José Echeverría, Gustavo Alberto Piro, Oscar Enrique Lezama, Luis Williams, Patricia Ana María Ferrer, Evelina Gloria |
author_role |
author |
author2 |
Parente, Juliana Elena Toledo, Maria Eugenia Escudero, Graciela Estela Laino, Carlos H. Martínez Medina, Juan José Echeverría, Gustavo Alberto Piro, Oscar Enrique Lezama, Luis Williams, Patricia Ana María Ferrer, Evelina Gloria |
author2_role |
author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Bioquímica Drug design X-ray crystal structure Pharmacological activities Bioavailability |
topic |
Bioquímica Drug design X-ray crystal structure Pharmacological activities Bioavailability |
dc.description.none.fl_txt_mv |
In the current study the ability of copper complex to exert multiple biological activities is combined with the pharmacological action of sertraline (SerH2Cl, antidepressant drug). The hydrated and anhydrous forms of the tetrachlorocuprate(II) salts, namely (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4], were synthesized and characterized by physicochemical methods. The crystal structures were determined by X-ray diffraction methods. The hydrate complex crystallizes in the monoclinic P21 space group with a =8.0807(2) Å, b =36.2781(8) Å, c =12.6576(3) Å, β =95.665(2)°, and Z =4 molecules per unit cell and the un-hydrate in P21 with a =13.8727(6) Å, b =7.5090(3) Å, c= 18.618(1) Å, β =104.563(6)°, and Z =2. It has been suggested that Cu(II) ions might be critical in the development of mood disorders, showed potent biocidal activity, and also acted as analgesic adjuvant. To improve sertraline efficiency, the antidepressant and analgesic activities of the complex have been assessed in rats denoting a marked synergistic effect. Antithyroid and antimicrobial activities were also evaluated. Because depressive disorders and hyperthyroidism diseases led to an oxidative stress state, antioxidant capability has also been tested. The complex behaved as a good superoxide radical scavenger (IC50=6.3 × 10−6 M). The ability of the complex to act as bromoperoxidase mimic was assessed. A pseudofirst order constant of k = 0.157 ± 0.007 min−1 has been determined. The complex evidences promising biological-pharmacological activities and the albumin binding studies showed a Kb of 2.90 ×103 M−1 showing an improvement in the uptake of sertraline by albumin at 8 h incubation (time required for effective interaction of sertraline with the protein). Centro de Química Inorgánica Instituto de Física La Plata |
description |
In the current study the ability of copper complex to exert multiple biological activities is combined with the pharmacological action of sertraline (SerH2Cl, antidepressant drug). The hydrated and anhydrous forms of the tetrachlorocuprate(II) salts, namely (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4], were synthesized and characterized by physicochemical methods. The crystal structures were determined by X-ray diffraction methods. The hydrate complex crystallizes in the monoclinic P21 space group with a =8.0807(2) Å, b =36.2781(8) Å, c =12.6576(3) Å, β =95.665(2)°, and Z =4 molecules per unit cell and the un-hydrate in P21 with a =13.8727(6) Å, b =7.5090(3) Å, c= 18.618(1) Å, β =104.563(6)°, and Z =2. It has been suggested that Cu(II) ions might be critical in the development of mood disorders, showed potent biocidal activity, and also acted as analgesic adjuvant. To improve sertraline efficiency, the antidepressant and analgesic activities of the complex have been assessed in rats denoting a marked synergistic effect. Antithyroid and antimicrobial activities were also evaluated. Because depressive disorders and hyperthyroidism diseases led to an oxidative stress state, antioxidant capability has also been tested. The complex behaved as a good superoxide radical scavenger (IC50=6.3 × 10−6 M). The ability of the complex to act as bromoperoxidase mimic was assessed. A pseudofirst order constant of k = 0.157 ± 0.007 min−1 has been determined. The complex evidences promising biological-pharmacological activities and the albumin binding studies showed a Kb of 2.90 ×103 M−1 showing an improvement in the uptake of sertraline by albumin at 8 h incubation (time required for effective interaction of sertraline with the protein). |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/104864 |
url |
http://sedici.unlp.edu.ar/handle/10915/104864 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/0162-0134 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinorgbio.2017.05.012 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
dc.format.none.fl_str_mv |
application/pdf 76-89 |
dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
reponame_str |
SEDICI (UNLP) |
collection |
SEDICI (UNLP) |
instname_str |
Universidad Nacional de La Plata |
instacron_str |
UNLP |
institution |
UNLP |
repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
_version_ |
1844616105684893696 |
score |
13.070432 |